ReviewCurrent diabetes reviews2013

New player on an old field; the keap1/Nrf2 pathway as a target for treatment of type 2 diabetes and metabolic syndrome.

Dionysios V Chartoumpekis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.